<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9576">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05695118</url>
  </required_header>
  <id_info>
    <org_study_id>SNUH-2022-3238</org_study_id>
    <nct_id>NCT05695118</nct_id>
  </id_info>
  <brief_title>Body Composition and Fatty Liver Disease</brief_title>
  <official_title>Analysis of the Prognostic Correlation Between Body Composition Analysis and Fatty Liver Progression in Patients With Fatty Liver Using Low-dose CT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates relationship between fatty liver prognosis and body composition&#xD;
      analysis result based on non-contrast low dose CT in patients with fatty liver disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 10, 2023</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>relationship between body composition analysis result from CT and liver fat fraction</measure>
    <time_frame>6 month after CT acquisition</time_frame>
    <description>relationship between visceral fat volume fraction (obtained from CT analysis using automatic body segmentation, unitless (visceral fat fraction = visceral fat volume/total body volume)) and CAP value of fibroscan</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ratio of appropriate non-contrast low dose abdomen CT acquisition &amp; analysis</measure>
    <time_frame>6 month after CT acquisition</time_frame>
    <description>Number of CT scan with effective dose &lt; 1.5 mSv AND successful automatic body composition analysis (without manual editing) divided by total number of CT scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relationship between body composition analysis result from CT and hepatic fibrosis</measure>
    <time_frame>6 month after CT acquisition</time_frame>
    <description>relationship between visceral fat volume fraction (CT analysis using automatic body segmentation, unitless (visceral fat fraction = visceral fat volume/total body volume)) and liver stiffness value of fibroscan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>agreement between body composition analysis result from CT and bioelectrical impedance analysis (Inbody test)</measure>
    <time_frame>6 month after CT acquisition</time_frame>
    <description>agreement of visceral fat, subcutaneous fat, muscle amount between CT based body composition and Inbody test results</description>
  </secondary_outcome>
  <other_outcome>
    <measure>incidence of incidental finding</measure>
    <time_frame>6 month after CT acquisition</time_frame>
    <description>incidentally detected findings on low-dose abdomen CT</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Fatty Liver</condition>
  <arm_group>
    <arm_group_label>non-contrast low-dose abdomen CT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>non-contrast low-dose abdomen CT (target effective dose: &lt; 1.5 mSv). CT based body composition analysis is performedd with commercially available automatic segmentation software (DeepCatch, Medical IP, South Korea).</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Non-contrast low-dose abdomen CT</intervention_name>
    <description>target effective dose: &lt; 1.5 mSv It is performed twice in 6-month interval.</description>
    <arm_group_label>non-contrast low-dose abdomen CT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Fibroscan</intervention_name>
    <description>Fibroscan is performed within a week of low-dose CT. It is used as a reference standard of hepatic fibrosis and steatosis.</description>
    <arm_group_label>non-contrast low-dose abdomen CT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>bioelectrical impedance analysis (BIA)</intervention_name>
    <description>BIA test is performed on the same day of low-dose CT. Commercially available model (Inbody 270) is used.</description>
    <arm_group_label>non-contrast low-dose abdomen CT</arm_group_label>
    <other_name>Inbody test (commercial name)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  metabolic dysfunction-associated fatty liver disease (fatty liver with&#xD;
             overweight/obesity, or type II DM or other metabolic dysfunction)&#xD;
&#xD;
          -  or non-alcoholic fatty liver disease with liver function test abnormality&#xD;
&#xD;
          -  signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  chronic hepatitis B or C&#xD;
&#xD;
          -  other disease related to fatty liver such as glycogen storage disease, lipodystrophy,&#xD;
             familial combined hyperlipidemia, hypobetalipoproteinemia, Weber-Christian syndrome or&#xD;
             abetalipoproteinemia&#xD;
&#xD;
          -  on medication related to hepatic steatosis (tamoxifen, steroid, valproic acid,&#xD;
             methotrexate, amiodarone)&#xD;
&#xD;
          -  diabetes after pancreatectomy&#xD;
&#xD;
          -  history of total parenteral nutrition in 6 months&#xD;
&#xD;
          -  pregnancy or nursing mother&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeong Min Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hyuna Jung</last_name>
    <phone>82-2-2072-4177</phone>
    <email>jha5375@snu.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jeong Hee Yoon, MD</last_name>
    <phone>82-2-2072-2293</phone>
    <email>cinamon1@snu.ac.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyuna Jung, RN</last_name>
      <phone>82-2-2072-4177</phone>
      <email>jha5375@snu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Jeong Min Lee, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2023</verification_date>
  <study_first_submitted>December 24, 2022</study_first_submitted>
  <study_first_submitted_qc>January 14, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2023</study_first_posted>
  <last_update_submitted>February 10, 2023</last_update_submitted>
  <last_update_submitted_qc>February 10, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Jeong Min Lee</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>CT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

